Researchers at the University of California San Diego have uncovered a connection between the topography of the human genome and the presence of mutations in human cancer.
FDA OKs Amivantamab as First-Line Lung Cancer Treatment
The FDA approved amivantamab (Rybrevant) plus combination chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) in patients whose tumors harbor EGFR exon
March 5, 2024